Novel Lp(a) lowering therapies predicted to be cost effective

If novel Lp(a) lowering therapies are released at comparable annual costs to other siRNA therapies, they are likely to be cost-effective for secondary prevention of cardiovascular disease, a preliminary health technology assessment presented by Professor Zanfina Ademi from Monash University, Melbourne, Australia, has shown. However, prices would need to be much lower if novel therapies were used for primary prevention.